XML 115 R21.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENT	3 Months Ended
SUBSEQUENT EVENT	Jun. 30, 2013
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On July 18, 2013, the Company completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, Inc. for $485 million in cash. The Company was entitled to these rights pursuant to a royalty agreement between Celera Corporation (which the Company acquired in May 2011) and Pharmacyclics, Inc. The Company will account for this transaction as a sale in the third quarter of 2013 since the Company has transferred all of its substantive rights related to these royalty rights.